Sugi Predict

Sugi Predict / Targets / RAD51

RAD51

DNA repair protein RAD51 homolog 1 · Q06609 · RAD51 on Sugi Atlas →

11,517 patent compounds predicted against RAD51, 6,918 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL439382 SCHEMBL439382 1.00 11/20
SCHEMBL602304 SCHEMBL602304 0.58 11/20
SCHEMBL1695298 SCHEMBL1695298 0.62 10/20
SCHEMBL1695301 SCHEMBL1695301 0.62 10/20
SCHEMBL2163050 SCHEMBL2163050 0.57 10/20
SCHEMBL893765 SCHEMBL893765 0.60 8/20
SCHEMBL1169584 SCHEMBL1169584 0.60 8/20
SCHEMBL758498 SCHEMBL758498 0.46 7/20
SCHEMBL38212 SCHEMBL38212 0.72 6/20
SCHEMBL38213 SCHEMBL38213 0.72 6/20
SCHEMBL439381 SCHEMBL439381 0.70 6/20
SCHEMBL439383 SCHEMBL439383 0.70 6/20
SCHEMBL2163077 SCHEMBL2163077 0.60 6/20
SCHEMBL1310914 SCHEMBL1310914 0.51 6/20
SCHEMBL1471669 SCHEMBL1471669 0.46 6/20
SCHEMBL832842 SCHEMBL832842 0.43 6/20
SCHEMBL25796 SCHEMBL25796 0.81 5/20
SCHEMBL175934 SCHEMBL175934 0.81 5/20
SCHEMBL2162701 SCHEMBL2162701 0.64 5/20
SCHEMBL1563459 SCHEMBL1563459 0.62 5/20

Clinical trials — most relevant to RAD51 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency PHASE3UNKNOWN
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency PHASE2/PHASE3RECRUITING
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. PHASE2COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation PHASE2RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer PHASE2ACTIVE_NOT_RECRUITING
Olaparib in Treating Patients With Stage IV Pancreatic Cancer PHASE2COMPLETED
Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) PHASE2COMPLETED
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors PHASE2COMPLETED
M6620 (VX-970) in Selected Solid Tumors PHASE2COMPLETED
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer PHASE2ACTIVE_NOT_RECRUITING
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma PHASE2ACTIVE_NOT_RECRUITING
Niraparib and Dostarlimab in HRD Solid Tumors PHASE2UNKNOWN
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA PHASE2ACTIVE_NOT_RECRUITING
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency PHASE2RECRUITING
The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation PHASE2UNKNOWN
Olaparib In Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) PHASE2RECRUITING
Efficacy and Safety of PARPi to Treat Pancreatic Cancer PHASE2COMPLETED
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer PHASE2ACTIVE_NOT_RECRUITING
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency PHASE2COMPLETED
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency PHASE2WITHDRAWN
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers PHASE1RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer EARLY_PHASE1COMPLETED
A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer nanCOMPLETED
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study nanRECRUITING
A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RAD51 binder may also engage these)

ProteinNameSimilarity
P70099 — 1.000 P70099 →
O77507 — 1.000 O77507 →
Q8MKI8 — 1.000 Q8MKI8 →
Q08297 — 1.000 Q08297 →
Q2KJ94 — 1.000 Q2KJ94 →
Q91917 — 1.000 Q91917 →
Q91918 — 1.000 Q91918 →
Q39009 — 1.000 Q39009 →
P37383 — 1.000 P37383 →
Q96449 — 1.000 Q96449 →
B8BM09 — 1.000 B8BM09 →
Q7GBF8 — 1.000 Q7GBF8 →
P94102 — 1.000 P94102 →
P37384 — 1.000 P37384 →
A6VGG2 — 1.000 A6VGG2 →
Q27297 — 1.000 Q27297 →
Q40134 — 1.000 Q40134 →
Q67EU8 — 0.999 Q67EU8 →
Q14565 — 0.998 Q14565 →
A9AA90 — 0.998 A9AA90 →
P0CW59 — 0.998 P0CW59 →
A4FWV5 — 0.998 A4FWV5 →
P0CW58 — 0.997 P0CW58 →
Q99133 — 0.997 Q99133 →
O42634 — 0.997 O42634 →
P25453 — 0.996 P25453 →
Q7GBF7 — 0.996 Q7GBF7 →
O73948 — 0.996 O73948 →
Q9XED7 — 0.995 Q9XED7 →
Q7EAG4 — 0.995 Q7EAG4 →